[1] Secchiero P,Coralina D,Rimondi E,et al.Activation of the p53 pathwaydown-regulates the osteoprotegerin expression and release by vascularendothelial cells [J].Blood,2008,111 ( 3 ):1287-1294.
[2] Ueda H,Mitsusada N,Harimoto K, et al.Glycosylated hemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantation in patients with diabetes mellitus [J].Cardiology,2010,116( 1):51-57.
[3] Morony S,Tintut Y,Zhang Z, et al.Osteoprotegerin inhibitsvascular cal-cification without affecting atherosclerosis in ldlrmice[J].Circulation,2008,117( 3):411-420.
[4] AvignonA,Sultan A,Piot C,et al.Osteoprotegerin is associated withsilent coronary artery disease in high-risk butasymptomatic type 2 diabeticpatients[J].Diabetes Care, 2005,28( 9):2176-2180.
[5] Ren MY, Sui SJ, Zhang Y, et al.Increased plasma osteeoprotegerinlevels are associated with the presence and severity of acute coronarysyndrome [J].Acta Cardio,2008,63( 5):615-622.
[6] Blankenberg S,Zeller T,Saarela O,et al.Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk,genetics,archiving,and monograph( MORGAM) biomarker project[J].Circulation,2010,121( 22):2388-2397.
[7] Melander O,Newton-Cheh C,Almgren P,et al.Novel and conventional biomarkers for prediction of incident cardiovascular events in the community[J].JAMA,2009,302( 1):49-57.
[8] Ridker PM,Buring JE,Rifai N, et al.Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score [J].JAMA,2007,297( 6):611-619.
[9] Calkin AC,Allen TJ.Diabetes mellitus-associatedat herosclerosis: mechanisms involved and potential for pharmacological invention[J].Am J Cardiovasc Drugs,2006,6( 1):15-40.